Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BCYC
BCYC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCYC News
Bicycle Therapeutics Reports Q1 Earnings Miss
Apr 30 2026
seekingalpha
Bicycle Therapeutics Presents Five Abstracts at AACR Annual Meeting 2026
Mar 18 2026
Newsfilter
Bicycle Therapeutics Restructures and Lays Off 30% of Workforce
Mar 17 2026
seekingalpha
Bicycle Therapeutics Q4 Earnings Exceed Expectations
Mar 17 2026
seekingalpha
Bicycle Therapeutics Appoints New CFO
Feb 03 2026
seekingalpha
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
Dec 16 2025
Businesswire
Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
Dec 16 2025
Newsfilter
Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%
Dec 11 2025
PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Nov 20 2025
PRnewswire
Citizens Upholds Outperform Rating for Bicycle Therapeutics plc - Depositary Receipt (BCYC) Market
Nov 01 2025
NASDAQ.COM
Citizens Upgrades Bicycle Therapeutics to Market Outperform and Increases Price Target to $12
Oct 31 2025
Benzinga
Itron Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Oct 31 2025
Benzinga
4 Analysts Assess Bicycle Therapeutics: What You Need To Know
Aug 12 2025
Benzinga
JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $10
Aug 12 2025
Benzinga
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Jul 31 2025
Newsfilter
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
Jul 17 2025
Benzinga
Show More News
